Novartis presented phase 2 data indicating its recently approved urticaria drug Rhapsido produced higher response rates in a food allergy cohort across three dose levels. The company framed the data as support for evaluating Rhapsido in broader allergic disease indications beyond chronic hives. Novartis is reviewing the full dataset to decide on next steps, including potential phase 3 planning or regulatory engagement for new indications. The move shows how approved agents are being redeployed into adjacent allergic and immunologic conditions. Clinicians and payers will scrutinize efficacy magnitude and safety in the food‑allergy population to assess whether Rhapsido could become a differentiated oral immunomodulator in a crowded allergy drug landscape.